UCB (WBAG:UCB) - Stock Price, News & Analysis

UCB Stock Overview

A biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.

About the company

UCB fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	1/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 65.4% below our estimate of its fair value

Earnings are forecast to grow 35.5% per year

Risk Analysis

Profit margins (4.4%) are lower than last year (6.5%)

UCB SA Competitors

Jiangsu Hengrui Medicine

SHSE:600276

CN¥277.6b

Otsuka Holdings

TSE:4578

JP¥4.3t

Takeda Pharmaceutical

TSE:4502

JP¥6.8t

Astellas Pharma

TSE:4503

JP¥3.1t

Price History & Performance

Summary of all time highs, changes and price drops for UCB
Historical stock prices
Current Share Price	€164.75
52 Week High	€166.80
52 Week Low	€66.04
Beta	0.36
11 Month Change	1.70%
3 Month Change	20.43%
1 Year Change	100.43%
33 Year Change	75.86%
5 Year Change	150.08%
Change since IPO	149.47%

Recent updates

Shareholder Returns

	UCB	AT Pharmaceuticals	AT Market
7D	2.8%	-2.9%	-0.1%
1Y	100.4%	13.0%	6.5%

Return vs Industry: UCB exceeded the Austrian Pharmaceuticals industry which returned 13% over the past year.

Return vs Market: UCB exceeded the Austrian Market which returned 6.5% over the past year.

Price Volatility

Is UCB's price volatile compared to industry and market?
UCB volatility
UCB Average Weekly Movement	3.9%
Pharmaceuticals Industry Average Movement	5.2%
Market Average Movement	3.5%
10% most volatile stocks in AT Market	6.0%
10% least volatile stocks in AT Market	1.9%

Stable Share Price: UCB has not had significant price volatility in the past 3 months.

Volatility Over Time: UCB's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1925	9,000	Jean-Christophe Tellier	www.ucb.com

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome.

UCB SA Fundamentals Summary

How do UCB's earnings and revenue compare to its market cap?
UCB fundamental statistics
Market cap	€31.00b
Earnings (TTM)	€240.00m
Revenue (TTM)	€5.45b

129.2x

P/E Ratio

5.7x

P/S Ratio

Is UCB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
UCB income statement (TTM)
Revenue	€5.45b
Cost of Revenue	€1.76b
Gross Profit	€3.70b
Other Expenses	€3.46b
Earnings	€240.00m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Feb 27, 2025

Earnings per share (EPS)	1.27
Gross Margin	67.80%
Net Profit Margin	4.40%
Debt/Equity Ratio	31.8%

How did UCB perform over the long term?

See historical performance and comparison

Dividends

0.8%

Current Dividend Yield

108%

Payout Ratio

UCB Stock Overview

Rewards

Risk Analysis

UCB SA Competitors

SHSE:600276

CN¥277.6b

TSE:4578

JP¥4.3t

TSE:4502

JP¥6.8t

TSE:4503

JP¥3.1t

Price History & Performance

Recent News & Updates

New minor risk - Profit margin trend

First half 2024 earnings released: EPS: €1.10 (vs €1.64 in 1H 2023)

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

Insufficient new directors

UCB SA to Report First Half, 2024 Results on Jul 25, 2024

Recent updates

New minor risk - Profit margin trend

First half 2024 earnings released: EPS: €1.10 (vs €1.64 in 1H 2023)

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

Insufficient new directors

UCB SA to Report First Half, 2024 Results on Jul 25, 2024

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

Full year 2023 earnings released: EPS: €1.81 (vs €2.22 in FY 2022)

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

First half 2023 earnings released: EPS: €1.64 (vs €2.10 in 1H 2022)

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

Upcoming dividend of €0.93 per share at 1.5% yield

Full year 2022 earnings released: EPS: €2.22 (vs €5.58 in FY 2021)

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

UCB SA to Present Data At the American Epilepsy Society 76Th Annual Meeting 2022 Supporting A Decades-Long Commitment to Transforming Epilepsy Care

UCB Announces the Publication of Long-Term Open-Label Extension (OLE) Study Results of FINTEPLA® (Fenfluramine) CIV in Epilepsia

UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients

UCB Announces the First Presentation of Long-Term, 52-Week Data from Three Phase 3 Studies Evaluating the Efficacy and Safety of Bimekizumab in Adults with Active Psoriatic Arthritis

UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study

First half 2022 earnings released

UCB, Announces New 24-Week Data from Two Phase 3 Studies, Be Mobile 1 and Be Mobile 2

UCB SA Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to Be Presented At EULAR 2022

UCB SA, Annual General Meeting, Apr 27, 2023

UCB Presents Efficacy and Safety Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis

UCB Announces Jama Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of Fintepla® (Fenfluramine) Oral Solution in Lennox-Gastaut Syndrome

UCB SA Announces Oral Solution Civ Approves for Treatment of Seizures Associated with Lennox-Gastaut Syndrome

UCB SA, Annual General Meeting, Apr 28, 2022

UCB Announces Positive Data in Myasthenia Gravis with Zilucoplan Phase 3 Study Results

UCB Announces Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

UCB SA Announces Positive Top-Line Interim Analysis Results Showing That the Phase 3 Be Mobile 1 Study Met the Primary and All Ranked Secondary Endpoints

UCB SA Announces Positive Top-Line Interim Analysis Results from the Phase 3 Be Mobile 2 Study

UCB Announces Positive Phase 3 Results for Rozanolixizumab in Generalized Myasthenia Gravis

First half 2021 earnings released: EPS €3.00 (vs €1.92 in 1H 2020)

UCB Announces New Data from Rheumatology Portfolio Demonstrates Real World Value for Patients with axSpA, PsA, and Women of Childbearing Age

Independent Vice Chairman Pierre Gurdjian has left the company

Chairman Diégo du de Bergendal has left the company

Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs

Full year 2020 earnings released: EPS €3.87 (vs €4.22 in FY 2019)

New 90-day low: €83.86

UCB Announces Changes on Board of Directors

New 90-day low: €84.30

UCB SA to Report First Half, 2021 Results on Jul 29, 2021

doc.ai and UCB Teams Up to Develop Breakthrough Artificial Intelligence Models to Advance Care

UCB and Stanford Medicine Establish Multi-Year Collaboration

UCB Announces U.S. Food and Drug Administration Approval of VIMPAT